TW200938223A - Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7) - Google Patents

Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7) Download PDF

Info

Publication number
TW200938223A
TW200938223A TW097145713A TW97145713A TW200938223A TW 200938223 A TW200938223 A TW 200938223A TW 097145713 A TW097145713 A TW 097145713A TW 97145713 A TW97145713 A TW 97145713A TW 200938223 A TW200938223 A TW 200938223A
Authority
TW
Taiwan
Prior art keywords
antibody
seq
group
human
cancer
Prior art date
Application number
TW097145713A
Other languages
English (en)
Chinese (zh)
Inventor
Jonathan Alexander Terrett
Chetana Rao-Naik
Chin Pan
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of TW200938223A publication Critical patent/TW200938223A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
TW097145713A 2007-11-30 2008-11-26 Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7) TW200938223A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US503407P 2007-11-30 2007-11-30

Publications (1)

Publication Number Publication Date
TW200938223A true TW200938223A (en) 2009-09-16

Family

ID=40718460

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097145713A TW200938223A (en) 2007-11-30 2008-11-26 Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7)

Country Status (11)

Country Link
US (1) US20120027782A1 (enExample)
EP (1) EP2229187A2 (enExample)
JP (1) JP2011505146A (enExample)
KR (1) KR20100101124A (enExample)
CN (1) CN101939028A (enExample)
AR (1) AR069903A1 (enExample)
AU (1) AU2008334076A1 (enExample)
CL (1) CL2008003527A1 (enExample)
MX (1) MX2010005966A (enExample)
TW (1) TW200938223A (enExample)
WO (1) WO2009073546A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957539B1 (en) 2005-12-08 2013-04-17 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN106967062A (zh) 2008-11-03 2017-07-21 辛塔佳股份有限公司 新型cc‑1065类似物及其缀合物
PT3056203T (pt) 2010-04-21 2018-02-15 Syntarga Bv Conjugados de análogos de cc-1065 e ligantes bifuncionais
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
AU2012296951B2 (en) * 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
IL290330B2 (en) * 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
CN105899235B (zh) 2014-01-10 2019-08-30 斯索恩生物制药有限公司 用于纯化cys连接的抗体-药物缀合物的方法
SG11201608953WA (en) 2014-04-30 2016-11-29 Pfizer Anti-ptk7 antibody-drug conjugates
ES2901705T3 (es) 2014-06-06 2022-03-23 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
RS60998B1 (sr) 2014-11-21 2020-11-30 Bristol Myers Squibb Co Antitela koja sadrže modifikovane regione teškog lanca
SI3221363T1 (sl) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
CA2971732A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11685787B2 (en) 2017-05-16 2023-06-27 Bristol-Myers Squibb Company Treatment of cancer with anti-GITR agonist antibodies
IL270596B1 (en) 2017-05-25 2025-09-01 Bristol Myers Squibb Co Antibodies comprising modified heavy constant region for use in treating cancer
CN113260384A (zh) 2018-11-05 2021-08-13 西纳福克斯股份有限公司 用于靶向表达trop-2的肿瘤的抗体缀合物
CN110845480B (zh) * 2019-11-22 2022-03-15 荣昌生物制药(烟台)股份有限公司 一种双功能细胞毒素及其用途
US20250340670A1 (en) * 2020-07-16 2025-11-06 UIF, (University Industry Foundation), Yonsei University Antibody specifically binding to ptk7 and use thereof
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
JP2025510623A (ja) * 2022-03-23 2025-04-15 シンアフィックス ビー．ブイ． Ｐｔｋ７を発現する腫瘍を標的化するための抗体コンジュゲート
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
WO2024054030A1 (ko) * 2022-09-06 2024-03-14 연세대학교 산학협력단 항-ptk7 항체 및 이의 용도
CN118852442A (zh) * 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
WO2025040588A1 (en) * 2023-08-18 2025-02-27 Oncoinvent As Monoclonal anti-ptk7 antibodies and derivatives
WO2025072406A1 (en) * 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1423110A4 (en) * 2001-09-07 2005-04-27 Scripps Research Inst CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EP1747021B1 (en) * 2004-05-19 2015-09-09 E. R. Squibb & Sons, L.L.C. Self-immolative linkers and drug conjugates
EP2354163A3 (en) * 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
EP1957539B1 (en) * 2005-12-08 2013-04-17 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use

Also Published As

Publication number Publication date
CL2008003527A1 (es) 2009-10-09
AR069903A1 (es) 2010-03-03
KR20100101124A (ko) 2010-09-16
CN101939028A (zh) 2011-01-05
EP2229187A2 (en) 2010-09-22
US20120027782A1 (en) 2012-02-02
JP2011505146A (ja) 2011-02-24
WO2009073546A3 (en) 2009-12-30
WO2009073546A2 (en) 2009-06-11
AU2008334076A1 (en) 2009-06-11
MX2010005966A (es) 2010-06-15

Similar Documents

Publication Publication Date Title
TW200938223A (en) Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7)
JP5401639B2 (ja) タンパク質チロシンキナーゼ７（ｐｔｋ７）に対するヒトモノクローナル抗体およびそれらの使用
CN101636502B (zh) 结合cd19的人类抗体及其用途
JP5535074B2 (ja) メソテリンに結合するヒト抗体およびその使用
KR101552735B1 (ko) 씨디22에 결합하는 인간 항체 및 이의 용도
US8420084B2 (en) Fully human antibodies specific to CADM1
US20110085970A1 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
US20090162372A1 (en) Fibronectin ed-b antibodies, conjugates thereof, and methods of use
JP2011505371A (ja) 抗−ｒｇ−１抗体の複合体
HK1164332B (en) Fully human antibodies specific to cadm1
HK1164332A (en) Fully human antibodies specific to cadm1
MX2008006792A (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
HK1185085B (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fuco-syl-gm1